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Introduction. Post-licensure vaccine safety studies are essential 
to identify uncommon events that may be difficult to assess during 
pre-licensure studies. The aim of our study was to evaluate the 
safety of serogroup C meningococcal conjugate (MCC) vaccine 
in Tuscany from 2005 to 2012. Methods. All adverse events (AEs) 
to MCC vaccine notified from 2005 to 2012 were obtained from 
the regional health authority.
Results. Following 451,570 doses administered, 110 suspected 
AEs were notified (mean annual reporting rate: 2.8/10,000 
doses). The most frequently AE reported was fever (60%), fol-
lowed by swelling at the injection site (11%) and febrile seizures 
(10%). Overall, 77.3% of cases were not severe, while 21.8% 
required hospitalization. Almost four months after the receipt of 
the vaccine, a one-year-old infant was diagnosed with a pervasive 
developmental disorder with disturbance of speech, but any link 
with the vaccinations received was refuted. Most AEs (80.9%) 
occurred after co-administration with other vaccines, especially 
with MMR or MMRV vaccines (42.7%) or the DTPa-HBV-IPV/
Hib vaccine (33.7%).
Discussion. Our study confirmed the high level of safety of MCC 
vaccine in Tuscany: AEs proved rare and all cases had only tem-
porary and self-resolving consequences. As usually only the most 
severe suspected AEs are reported, the true proportion of AEs 
requiring hospitalization was most probably overestimated, and it 
is plausible that most of these cases were in fact only temporally 
related.
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Summary
Introduction
Invasive meningococcal disease (IMD), a potentially 
life-threatening acute disease with a rapid evolution 
caused by the gram-negative, encapsulated and coffee-
bean shaped diplococcus Neisseria meningitides, still 
represents a global public health challenge, with around 
500,000 cases and 50,000 deaths occurring every year 
worldwide  [1]. IMD can be characterized by meningi-
tis, bacteremia, sepsis, pneumonia, or, less commonly, 
by localized infections such as arthritis, myocarditis, 
pericarditis and endophtalmitis  [2-4]. Prognosis con-
siderably improved after the introduction of antibiotic 
therapy, but the case fatality rate is still between 5 and 
10% in industrialized countries and up to 20% of survi-
vors suffer from lifelong sequelae, such as mental retar-
dation, seizures, bilateral hearing loss, low vision or loss 
of limbs caused by the tissue necrosis [5]. According to 
the bacterial capsular antigens, 12 serogroups of N. men-
ingitidis have been identified (A, B, C, 29E, H, I, K, L, 
Y, W135, X and Z), but those most often associated with 
the disease are serogroups A, B, C, X, Y and W135 [6]. 
In Europe, most meningococcal disease is caused by B 
and C serogroups. 
Effective vaccination programmes represent the most 
important tool to fight against the disease. Infections 
caused by serogroups A, C, Y and W135 can be pre-
vented by polysaccharide vaccines, which, however, are 
poorly immunogenic in children aged under two years 
and fail to induce immunological memory in people of 
any age, or by two types of conjugate vaccines, which 
allow the induction of immune memory also in children 
aged under two years [7]. The first, the meningococcal C 
conjugate (MCC) vaccine, is directed only against type 
C meningococcus; the capsular polysaccharide antigens 
are conjugated to an immunogenic protein, either to 
diphtheria toxoid, or to CRM197, a non-toxic mutant of 
diphtheria toxin, or to tetanus toxoid and may be used 
after the third month of age. Recently, tetravalent vac-
cines against the meningococcal groups A, C, W135 and 
Y, mainly recommended to travellers to Sub-Saharan 
Africa, have been made available.
In Italy, the previously increasing trend of serogroup 
C meningococcal disease dramatically declined after 
the introduction of a universal vaccination programme 
against Neisseria meningitidis serogroup C. Tuscany 
was the first Italian Region to approve, in 2005, a pol-
icy of active offer of MCC vaccine with three doses to 
all newborns at three, five and 13 months of age, and a 
catch-up until six years with a single dose. Immuniza-
tion with MCC vaccine was also recommended for sub-
jects of any age at risk for developing IMD [8]. In July 
2008, the newborn schedule turned to a single dose after 
the first year of age, at around 13 months. Therefore, 
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presently, at 13-15 months four vaccines are adminis-
tered: MCC, pneumococcal, hexavalent and MMR or 
MMRV vaccines [9]. The adoption of the new schedule 
was established in reason of the high herd immunity cre-
ated by the vaccination programme, as a result of which 
the incidence of meningococcal disease was reduced by 
80% in children under one year of age, not yet vaccinat-
ed [10]. Catch-up of children aged two to six years was 
maintained by offering a single dose, in order to create a 
solid immunity in the population. The vaccine is also of-
fered to the 12-14 years age group. With the recognition 
that on-going post-marketing monitoring is essential in 
order for the general population to maintain confidence 
in vaccine safety, the aim of the present study was to 
evaluate the safety and tolerability of MCC vaccine in 
Tuscany between 2005 and 2012 through an analysis of 
the suspected adverse events (AEs) to the MCC vaccine 
notified to the regional health authority since the inclu-
sion of the MCC vaccination in the recommended vac-
cination programme.
Materials and methods
The notification of a suspected AE following a vac-
cination is regulated by a Ministerial Decree issued in 
2003  [11]: the same procedure and reporting form as 
in the case of suspected AEs following pharmacologi-
cal treatments are used. Consistently with Directive 
2001/83/EC of the European Parliament and of the 
Council of 6 November 2001 on the Community code 
relating to medicinal products for human use, an AE is 
a noxious and unintended response to a medicinal prod-
uct used at normal dosages. A serious adverse reaction 
is an AE “which results in death, is life-threatening, re-
quires in-patient hospitalisation or prolongation of ex-
isting hospitalisation, results in persistent or significant 
disability or incapacity, or is a congenital anomaly/birth 
defect”. The reporting form, filled in by a healthcare 
worker, is sent to the pharmacovigilance unit of the re-
spective health service, data are registered through the 
national network of pharmacovigilance and sent to the 
regional health authority, as well as to the drug or vac-
cine manufacturer and to the Italian Medicines Agency, 
within seven days. The information regarding serious 
AEs are also made available to the European Medicines 
Agency and to the other EU Member States. The report-
ing form must include the patient’s initials, date of birth, 
gender, the description and the severity of the event, the 
effects caused, the name of the suspected drug or vac-
cine, possible risk factors and information on other vac-
cines/drugs that may have been co-administered.
As for vaccinations, the time of administration and the 
dose number are also reported, with the specification of 
the batch number and expiration date [11]. In the report-
ing form it must be specified whether the AE i) was not 
severe; ii) was severe requiring hospitalization but fol-
lowed by resolution; iii) was very severe, possibly with 
long-term consequences; iv) caused death.
Data regarding all AEs to MCC vaccine from 2005 to 
2012, collected by the Regional Health Authority, were 
obtained after been made anonymous. For each suspect-
ed AE the following information were made available: 
the specific numeric code assigned to the individual; 
the reporting local health unit; the date of occurrence; 
the subject’s age (due to privacy regulations the date 
of birth was not available) and gender of the subjects; 
type, severity and outcome of the reaction; the report-
ing source (hospital, general practice, primary care, drug 
store); the contact details of the person who reported the 
AE; the type of administration and data regarding other 
vaccines, drugs, herbal or homeopathic products or food 
supplements that may have been co-administered. Data 
analysis was performed using descriptive statistics in 
Microsoft Excel 2010.
Results
From 2005 to 2012, 451,570 doses of conjugate menin-
gococcal C vaccine were administered in Tuscany and, 
during this period, 110 cases of suspected AEs to the 
MCC vaccine were notified, with an average annual re-
porting rate of 2.8/10,000 doses. In Figure 1, the number 
of doses administered each year and the annual reporting 
rates are shown. In 2005, the average reporting rate was 
1.3/10,000 doses; it increased in the following years until 
2008. In that year the schedule was amended to a single 
dose at 13 months. In 2009, the reporting rate dropped 
to 1.3/10,000, then an increase of the annual reporting 
rate, up to 8.0/10,000 doses in 2012, was observed. The 
vaccine coverage at 24 months progressively increased 
from 65.8% in 2005, when the policy of active offer of 
MCC vaccine was introduced, to 90.5% in 2011; in 2012 
it was 89.4% (Fig. 2). Females and males were almost 
equally affected (51% males, 49% females). Given the 
recommended schedule, AEs mostly affected the young-
est age groups: 58.2% of AEs were reported in children 
Fig. 1. Number of doses administered per year and average an-
nual reporting rates of suspected adverse events following im-
munization with mCC vaccine per 10,000 doses administered, 
Tuscany, 2005-2012.
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aged one to two years, 15.5% in infants up to one year 
of age and 13.6% in children aged two to seven years 
(Tab. I). Most AEs, 25.5% and 19.1% respectively, were 
recorded in 2012 and 2008. 
Overall, the most frequently reported AE was fever 
(60%), followed by swelling at the injection site (11%). 
Ten cases of febrile seizures (10%) were reported. Four 
cases of non-febrile seizures (3.6%) and three cases 
(2.7%) of unspecified convulsions were also notified. 
Rash was also common (10%). Other suspected AEs 
were vomiting (7.2%), diarrhoea, drowsiness, agita-
tion/restlessness (4.5%), lymphadenopathy, persistent 
crying, pain at the injection site (3.6%). Two cases of 
thrombocytopenia purpura (1.8%), one of which classi-
fied as idiopathic, and one case of ataxia (1%) were also 
notified.
The majority of suspected AEs to MCC vaccine, 77.3%, 
were not severe, whereas approximately a fifth (21.8%) 
were severe and required patients’ hospitalization, but 
were followed by resolution (Fig. 3). Almost half (49%) 
of total suspected AEs occurred the same day the vac-
cine was administered, most of these (87%) were not se-
vere. Most febrile seizures (6/10) occurred between six 
and 11 days after vaccination.
Half of the 24 cases requiring hospitalization occurred 
after six days from the vaccination.
One third of hospitalized cases (8/24) was admitted to 
hospital due to convulsions (Fig. 4). Among these, 63% 
(N = 5) were febrile seizures. A fifth (5/24; 20.8%) were 
hospitalized for the onset of fever (all in children aged 
one). Another fifth was hospitalized due to disorders of 
the nervous system other than convulsions: two cases 
of hypotonia (one in a two-year-old; the other, followed 
by loss of consciousness, was reported in a two-month-
old); sleepiness and irritability were notified for a one-
year-old; an infant was admitted for absence seizure and 
hyperpyrexia; finally, a case of ataxia was reported in 
a one-year-old after concomitant administration with 
MMRV. The other causes of hospitalization were: de-
velopment of acute dyspnea or apnea accompanied by 
fever (n = 2); thrombocytopenic purpura (n = 2; one after 
co-administration with the MMRV vaccine); giant ur-
ticaria (n  =  1). In the case of an eight-year-old child, 
the cause of hospitalization was itchiness at the injection 
site.
In 2009, one suspected AE was classified as “very se-
vere, possibly with persistent consequences”: it was 
the case of a one-year-old infant, for whom a pervasive 
developmental disorder with disturbance of speech was 
reported about four months after the administration of 
the MCC vaccine. According to the recommendations of 
the regional vaccination plan, the child was vaccinated 
with MMRV and MCC vaccines in March and with the 
7-valent pneumococcal conjugate vaccine in April and 
in June. Any causal correlation with the MCC vaccine 
or with the other vaccines administered simultaneously 
or afterwards was refuted by the paediatrician, due to the 
lack of biological plausibility, and an autism spectrum 
disorder was hypothesized instead. The physician, how-
ever, was still not completely certain about the diagnosis 
as of July 2014.
Fig. 2. vaccination coverage with mCC vaccine at 24 months of 
age (%), Tuscany, 2006-2012.
Fig. 3. Number of suspected adverse events following immuniza-
tion with mCC vaccine by severity of the events, Tuscany, 2005-
2012. *  Lack of biological plausibility, **  Causal association not 
demonstrated.
Tab. I. Suspected Aes following immunization with mCC vaccine by age groups and year, Tuscany, 2005-2012. 
Age groups
2005
N (%)
2006
N (%)
2007
N (%)
2008
N (%)
2009
N (%)
2010
N (%)
2011
N (%)
2012
N (%)
Suspected AEs
2005-2012
N (%)
< 1 2 (20) 5 (45.5) 4 (33.3) 4 (19.0) 0 (0) 0 (0) 1 (6.7) 1 (3.6) 17 (15.5)
1-2 3 (30) 2 (18.2) 6 (50.0) 11  (52.4) 5 (83.3) 2 (28.6) 12 (80) 23 (82.1) 64 (58.2)
2-7 4 (40) 3 (27.3) 2 (16.7) 1  (4.8) 0 (0) 2 (28.6) 1 (6.7) 2 (7.1) 15 (13.6)
7-14 1 (10) 1 (9.1) 0 (0) 1 (4.8) 0 (0) 0 (0) 0 (0) 1 (3.6) 4 (3.6)
> 14 0 (0) 0 (0) 0 (0) 4 (19.0) 1 (16.7) 3 (42.9) 1 (6.7) 1 (3.6) 10 (9.1)
TOTAL N (%) * 10 (9.1) 11 (10.0) 12 (10.9) 21 (19.1) 6 (5.4) 7 (6.4) 15 (13.6) 28 (25.5) 110 (100)
* % on the total suspected Aes reported between 2005 and 2012.
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Most suspected AEs (89/110; 80.9%) occurred the same 
day of co-administration with other vaccines. Three vac-
cines, MCC included, were co-administered in 7.3% 
of AEs and a fourth vaccine was administered in one 
case (0.9%). The most common associations were those 
with the MMRV or the MMR vaccines (42.7%) and 
those with the hexavalent diphtheria-tetanus-acellular 
pertussis-hepatitis B virus-inactivated polio/Haemophi-
lus influenzae b (DTPa-HBV-IPV/Hib) vaccine (33.7%) 
(Fig. 5). The majority of suspected AEs following co-
administration with another vaccine (57%) occurred be-
tween 2009 and 2012, i.e. after the switch, in 2008, to a 
single dose at 13 months, age in which, according to the 
regional schedule, children are also immunized against 
MMR or MMRV. All ten cases of febrile seizures oc-
curred after co-administration with other vaccines: five 
after MMR vaccine, two after MMRV vaccine, two after 
the DTPa-HBV-IPV/Hib vaccine, and one after the vari-
cella virus vaccine. In Figure 6, the suspected AEs re-
ported following co-administration of MCC with MMR 
or MMRV vaccines and the vaccination coverage at 24 
months for measles and/or varicella containing vaccines 
are shown.
For seven severe cases that required hospitalization, data 
concerning the outcomes are missing. The causes of hos-
pitalization for these cases were: febrile seizures (n = 3); 
unspecified convulsions (n = 1); hypotonia (n = 1); idi-
opathic thrombocytopenic purpura (n = 1); and, finally, 
hyperpyrexia (n = 1). All other cases were followed by 
improvement or complete resolution.
Discussion
The development of the meningococcal serogroup C con-
jugated vaccine was prompted by the increasing number 
of serogroup C infections in the 1990s, especially in 
children under two years: these were cases that could 
not be prevented on account of the poor immunogenicity 
granted for this age group by the already available poly-
saccharide vaccine. The safety and the immunogenicity 
of MCC vaccine had been clearly evaluated in several 
pre-licensure trials [12-14]. The first country to imple-
ment a national MCC immunization programme, in No-
vember 1999, was the UK, where, in less than one year 
and a half, each individual aged under 18 years was im-
munised. The Committee on Safety of Medicines Expert 
Working Group assessed the MCC vaccine safety pro-
file during this immunisation campaign and concluded 
for its extremely favourable risks/benefits balance [15]. 
Post-licensure surveillance of vaccine safety is essential 
in order to identify uncommon events that may be dif-
ficult to assess during pre-licensure studies, when, usu-
ally, the small sample size and the relatively short period 
of observation only allow to describe the most common 
and expected AEs. Furthermore, the effects on suscepti-
ble individuals that might eventually become the target 
of vaccination strategies, such as subjects with medical 
conditions, are not commonly evaluated in pre-licen-
sure studies  [16]. Research in vaccine safety can help 
to maintain public confidence in immunizations and to 
prevent the decrease of vaccination coverage, the return 
of previously under control infectious diseases, as well 
as avoidable deaths [17]. As a matter of fact, at the pre-
sent time, vaccinations are at risk to become victims of 
their own success, especially in Western Europe, where 
some illnesses against which vaccines offer protection 
(e.g. haemophilus influenzae infections or diphtheria) 
have become so sporadic that even health professionals 
sometimes fail to appreciate the potential of one of the 
most successful tools for protecting the public’s health, 
and anti-vaccine movements have gained popularity in 
recent decades. When, very rarely, true severe adverse 
reactions to immunizations do arise, they are generally 
short-lived and can be treated under the circumstances in 
which vaccines are nowadays administered. However, 
although vaccines are recognized as the most effective 
and safest medical and public health interventions [18], 
second only to the development of safe water resourc-
es [19], yet, very rarely, they may cause severe AEs. It 
is therefore important to timely identify such events, so 
that regulatory actions can be promptly taken in order 
Fig. 4. Causes of hospitalization following mCC vaccine in Tuscany (2005-2012). * Five cases of convulsions out of eight were febrile seizures.
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Fig. 5. Suspected adverse events following immunization with mCC vaccine in co-administration with other vaccines, Tuscany, 2005-2012.
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to ensure that vaccines continue to have the desirable 
safety and quality profiles.
The aim of the present study was to evaluate the safety 
and tolerability of MCC vaccine in Tuscany since its in-
troduction into the regional immunization programme, 
through an analysis of the suspected AEs reported be-
tween 2005 and 2012. Due to privacy regulations, data 
were obtained anonymized, but we could assess the re-
porting rate per doses administered. Our findings con-
firmed the high level of safety and tolerability of the 
vaccine in Tuscany: AEs proved to be rare, the average 
annual reporting rate being 2.8/10,000 doses. The in-
crease of the reporting rates after 2009 reflects the transi-
tion from a three-dose to a single-dose schedule and the 
subsequent decreased denominators. The events notified 
were not severe in nearly four-fifths of the cases. All 
suspected AEs for whom the information on the outcome 
was available proved to be temporary and self-resolving. 
For the one severe suspected AE with probable perma-
nent disability, any causal relationship with the vaccines 
administered around the time of the onset of symptoms 
(pervasive developmental disorder with disturbance of 
speech) was conclusively ruled out by the paediatrician, 
due to the lack of biological plausibility. As for the most 
severe AEs registered, it is important to highlight that all 
febrile seizures registered occurred following co-admin-
istration with MMR, MMRV, DTPa-HBV-IPV/Hib or 
varicella vaccines. The risk of febrile seizures, generally 
occurring seven to 10 days after immunization, particu-
larly increases with MMR or MMRV vaccines: up to 3.4 
additional cases per 10,000 children [20, 21] and 5.8 ad-
ditional cases per 10,000 doses [22], respectively, have 
been described in the literature. Results from our study 
indeed confirmed the post-vaccine “peak period” for fe-
brile convulsions incidence.
Fig. 6. Suspected adverse events following mCC vaccination co-
administered with mmr or mmrv vaccine, and mmrv, mmr, v 
vaccination coverage at 24 months of age, Tuscany, 2009-2012. 
* For 2009, the vaccine coverage at 24 months is beyond 100%, 
because the information obtained by the regional authority re-
garded the combined mmr/mmrv vaccine coverage (separate 
data were not available) and about the monovalent varicella (v) 
vaccine coverage: these two values partly overlap, as mmr and v 
vaccines could be administered simultaneously in the same day.
One of the two cases of thrombocytopenic purpura that 
were registered can be put in causal correlation with the 
MMRV vaccine, since it occurred after co-administra-
tion with this vaccine, and while there is no evidence 
of an increased risk in children following immunization 
with MCC  [23], idiopathic thrombocytopenic purpura 
is a recognized adverse event of measles-containing 
vaccines [24]: in the literature up to 1 case per 22,300 
doses have been reported in association with these vac-
cines  [25-30]. Also the case of ataxia in one-year-old 
infant, which resulted in complete resolution, could be 
related to MMRV vaccine: it occurred after co-admin-
istration with this vaccine and transient ataxia has been, 
very rarely, reported after MMRV vaccinations in post-
marketing surveillance studies [31, 32].
Conclusions
Since usually only the most severe AEs are reported, 
the suspected AEs that required inpatient hospitalization 
(21.8%) in all likelihood overestimated the true propor-
tion of severe AEs. Most of these observed cases may 
be unrelated to the immunization, but have a temporal 
association with it. The increase in the reporting rate in 
the last two years of our period of observation (2011-
2012) is indeed noteworthy: it followed the publication 
of a study, in 2010, pointing at an increased risk for fe-
brile seizures in subjects immunized with the MMRV 
vaccine [33], which contributed to focus widespread at-
tention on the problem of adverse events following im-
munizations. The findings of the present study, which 
confirmed the high level of safety of the MCC vaccine, 
can contribute to support public health professionals in 
addressing parents’ concerns regarding the safety pro-
file of the vaccines recommended in our national and 
regional immunization programmes.
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